Trial Profile
A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Durvalumab
- Indications Advanced breast cancer; Colon cancer; Lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 24 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 25 Nov 2022 Planned End Date changed from 19 Dec 2022 to 30 Dec 2022.
- 07 Mar 2022 Planned End Date changed from 23 Feb 2022 to 19 Dec 2022.